Abstract
This review outlines factors that differentiate botulinum toxin serotypes and focuses on the unique features of the commercially available form of BoNT-B (i.e., Myobloc®/NeuroBloc®). A series of preclinical studies in Cynomolgus monkeys are reviewed. Each of these studies used electrophysiologic measures of changes in the compound muscle action potential (CMAP) following supramaximal nerve stimulation to evaluate the direct effects of the toxin in the injected muscle, as well as the spread of the effects to non-injected muscles. The results of 14 studies were summarized, including several that compared the effects of equivalent doses of BoNT-A and BoNT-B injected into muscles on the opposite side of the same monkey. There is clear evidence that when equivalent doses of BoNT-A and BoNT-B are assessed, there is greater spread to both nearby and remote non-injected muscles associated with BoNT-A. Similar studies in the mouse model demonstrated that high, but non-lethal, doses of BoNT-A unilaterally injected into the foot resulted in spread of the effects across the midline to the opposite non-treated foot, while there was no evidence of bilateral effects with equivalent unilateral injections of BoNT-B. Finally, this review summarizes a series of studies in the trapezius and gastrocnemius muscles of monkeys demonstrating that when doses producing equivalent initial effects of BoNT-A and BoNT-B are compared, the duration of effects and the time course of recovery are almost identical across toxins.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 690-696 |
| Number of pages | 7 |
| Journal | Toxicon |
| Volume | 54 |
| Issue number | 5 |
| DOIs | |
| State | Published - Oct 2009 |
Fingerprint
Keywords
- BoNT-A
- BoNT-B
- Compound muscle action potential
- Cynomolgus monkey model
- Myobloc/NeuroBloc
ASJC Scopus subject areas
- Toxicology
- Medicine(all)
Cite this
NeuroBloc®/Myobloc® : Unique features and findings. / Arezzo, Joseph C.
In: Toxicon, Vol. 54, No. 5, 10.2009, p. 690-696.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - NeuroBloc®/Myobloc®
T2 - Unique features and findings
AU - Arezzo, Joseph C.
PY - 2009/10
Y1 - 2009/10
N2 - This review outlines factors that differentiate botulinum toxin serotypes and focuses on the unique features of the commercially available form of BoNT-B (i.e., Myobloc®/NeuroBloc®). A series of preclinical studies in Cynomolgus monkeys are reviewed. Each of these studies used electrophysiologic measures of changes in the compound muscle action potential (CMAP) following supramaximal nerve stimulation to evaluate the direct effects of the toxin in the injected muscle, as well as the spread of the effects to non-injected muscles. The results of 14 studies were summarized, including several that compared the effects of equivalent doses of BoNT-A and BoNT-B injected into muscles on the opposite side of the same monkey. There is clear evidence that when equivalent doses of BoNT-A and BoNT-B are assessed, there is greater spread to both nearby and remote non-injected muscles associated with BoNT-A. Similar studies in the mouse model demonstrated that high, but non-lethal, doses of BoNT-A unilaterally injected into the foot resulted in spread of the effects across the midline to the opposite non-treated foot, while there was no evidence of bilateral effects with equivalent unilateral injections of BoNT-B. Finally, this review summarizes a series of studies in the trapezius and gastrocnemius muscles of monkeys demonstrating that when doses producing equivalent initial effects of BoNT-A and BoNT-B are compared, the duration of effects and the time course of recovery are almost identical across toxins.
AB - This review outlines factors that differentiate botulinum toxin serotypes and focuses on the unique features of the commercially available form of BoNT-B (i.e., Myobloc®/NeuroBloc®). A series of preclinical studies in Cynomolgus monkeys are reviewed. Each of these studies used electrophysiologic measures of changes in the compound muscle action potential (CMAP) following supramaximal nerve stimulation to evaluate the direct effects of the toxin in the injected muscle, as well as the spread of the effects to non-injected muscles. The results of 14 studies were summarized, including several that compared the effects of equivalent doses of BoNT-A and BoNT-B injected into muscles on the opposite side of the same monkey. There is clear evidence that when equivalent doses of BoNT-A and BoNT-B are assessed, there is greater spread to both nearby and remote non-injected muscles associated with BoNT-A. Similar studies in the mouse model demonstrated that high, but non-lethal, doses of BoNT-A unilaterally injected into the foot resulted in spread of the effects across the midline to the opposite non-treated foot, while there was no evidence of bilateral effects with equivalent unilateral injections of BoNT-B. Finally, this review summarizes a series of studies in the trapezius and gastrocnemius muscles of monkeys demonstrating that when doses producing equivalent initial effects of BoNT-A and BoNT-B are compared, the duration of effects and the time course of recovery are almost identical across toxins.
KW - BoNT-A
KW - BoNT-B
KW - Compound muscle action potential
KW - Cynomolgus monkey model
KW - Myobloc/NeuroBloc
UR - http://www.scopus.com/inward/record.url?scp=68849121142&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=68849121142&partnerID=8YFLogxK
U2 - 10.1016/j.toxicon.2009.03.009
DO - 10.1016/j.toxicon.2009.03.009
M3 - Article
C2 - 19286001
AN - SCOPUS:68849121142
VL - 54
SP - 690
EP - 696
JO - Toxicon
JF - Toxicon
SN - 0041-0101
IS - 5
ER -